Company: DNLI
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001714899-25-000066
Chunk: 205

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 15
Chunk 205
---
3831110.108/1/202419.1Denali Insider Trading Policy and Guidelines with Respect to Certain Transactions in Securities as amended through March 31, 2023.10-K001-3831110.352/28/202421.1Subsidiaries of the Registrant.———Filed herewith23.1Consent of Independent Registered Public Accounting Firm.———Filed herewith24.1Powers of Attorney (incorporated by reference to the signature page hereto)31.1Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act.———Filed herewith31.2Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act.———Filed herewith32.1*Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act.———Furnished herewith32.2*Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act.———Furnished herewith101The following materials from the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, formatted in Inline XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations and Comprehensive Loss, (iii) Consolidated Statements of Cash Flows (iv) Consolidated Statements of Stockholders’ Equity and (v) Notes to Consolidated Financial Statements.———Filed herewith104The cover page from the Company's Annual Report on Form 10-K for the year ended December 31, 2024, formatted in Inline XBRL (contained in Exhibit 101)———Filed herewith

178

*The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing. ÜPortions of the exhibit have been omitted pursuant to an order granted by the Securities and Exchange Commission for confidential treatment.#Certain confidential information contained in this exhibit has been omitted because it is both (i) not material and (